Featured Press Releases

Apotex Corp. Introduces Generic Fertility Treatment Injectable Cetrorelix® in the United States

Apotex Corp. Introduces Generic Fertility Treatment Injectable Cetrorelix® in the United States

Children’s Hospital Los Angeles completes its 100th retinal gene therapy procedure, advancing pediatric vision care.

Children’s Hospital Los Angeles completes its 100th retinal gene therapy procedure, advancing pediatric vision care.

  • 05 Dec 2024

His newly treated patients might show significant improvements on their eye chart tests, but Aaron...

TrueMed Partners with Alliance Pharmaceuticals Ltd to Combat Sophisticated Counterfeits Using AI-Powered Authentication

TrueMed Partners with Alliance Pharmaceuticals Ltd to Combat Sophisticated Counterfeits Using AI-Powered Authentication

Spyre Therapeutics Announces Inducement Award Grants

Spyre Therapeutics Announces Inducement Award Grants

Illumina

Illumina's Constellation Mapped Read technology uncovers hard-to-see genomic insights in the GeneDx pilot

Real-world data presented at TCT 2025 demonstrates that the EggNest™ Complete Radiation Protection System significantly reduces radiation exposure for the entire cath lab

Real-world data presented at TCT 2025 demonstrates that the EggNest™ Complete Radiation Protection System significantly reduces radiation exposure for the entire cath lab

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.

  • Johnson & Johnson
  • 06 Mar 2026
ulrich medical USA® Expands Commitment to Evidence-Based Spine Innovation; Appoints Alissa Calaway, RN, MSN as Director of U.S. Clinical Affairs

ulrich medical USA® Expands Commitment to Evidence-Based Spine Innovation; Appoints Alissa Calaway, RN, MSN as Director of U.S. Clinical Affairs

  • ulrich medical USA
  • 06 Mar 2026
Cognito Therapeutics Announces $105 Million Oversubscribed Series C Financing to Advance Spectris™ in Alzheimer’s Disease.

Cognito Therapeutics Announces $105 Million Oversubscribed Series C Financing to Advance Spectris™ in Alzheimer’s Disease.

  • Cognito Therapeutics
  • 05 Mar 2026
Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

  • Eton Pharmaceuticals
  • 04 Mar 2026
FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

  • US-Rx
  • 03 Mar 2026
30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

  • Merck & Co., Inc.
  • 03 Mar 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
March   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.